Year
2026
-
AHT – 424B3
-
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
-
AFB – DEFA14A
-
Brookfield Business Corporation Completes 2025 Annual Filings
-
Tenaris Files its 2025 Annual Report and its Annual Report on Form 20-F
-
CODI – SCHEDULE 13D/A [Amend]
-
PSEC – 424B2
-
BCV – SCHEDULE 13D/A [Amend]
-
PEO – SCHEDULE 13D/A [Amend]
-
PSEC – 424B2
-
FMN – N-23C-2
-
SPNT – 8-K
-
CYCC – 10-K
-
FAT – 8-K
-
CYCC – 8-K
-
TCBI – DEFA14A
-
XOMA – DEFA14A
-
NXDT – 8-K
-
XOMA – DEF 14A
-
STNG – 6-K
-
CNFR – 8-K
-
AL – 8-K
-
AHT – 8-K
-
MTB – 8-K
-
USM – 10-K/A [Amend]